Standout Papers

The global epidemiology of carbapenemase-producing Enterobacteriaceae 2016 2026 2019 2022 667
  1. The global epidemiology of carbapenemase-producing Enterobacteriaceae (2016)
    David van Duin, Yohei Doi Virulence
  2. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae (2017)
    David van Duin, Judith J. Lok et al. Clinical Infectious Diseases
  3. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations (2016)
    David van Duin, Robert A. Bonomo Clinical Infectious Diseases
  4. Multidrug-Resistant Bacteria in the Community (2016)
    David van Duin, David L. Paterson Infectious Disease Clinics of North America
  5. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections (2023)
    Pranita D. Tamma, Samuel L Aitken et al. Clinical Infectious Diseases
  6. Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase–Producing Enterobacterales, Carbapenem-ResistantAcinetobacter baumannii, andStenotrophomonas maltophiliaInfections (2021)
    Pranita D. Tamma, Samuel L Aitken et al. Clinical Infectious Diseases
  7. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), andPseudomonas aeruginosawith Difficult-to-Treat Resistance (DTR-P. aeruginosa) (2021)
    Pranita D. Tamma, Samuel L Aitken et al. Clinical Infectious Diseases
  8. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa) (2020)
    Pranita D. Tamma, Samuel L Aitken et al. Clinical Infectious Diseases
  9. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa) (2022)
    Pranita D. Tamma, Samuel L Aitken et al. Clinical Infectious Diseases
  10. Bacterial Infections After Burn Injuries: Impact of Multidrug Resistance (2017)
    Anne M. Lachiewicz, David J. Weber et al. Clinical Infectious Diseases

Immediate Impact

1 by Nobel laureates 28 from Science/Nature 74 standout
Sub-graph 1 of 22

Citing Papers

Multidrug-resistant Gram-negative bacterial infections
2025 Standout
Bacteriophage therapy for multidrug-resistant infections: current technologies and therapeutic approaches
2025 Standout
35 intermediate papers

Works of David van Duin being referenced

Antibacterial Resistance Leadership Group 2.0: Back to Business
2021
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
2017 Standout
and 18 more

Author Peers

Author Last Decade Papers Cites
David van Duin 5283 3172 2735 173 9.3k
Helen Giamarellou 7289 4661 4600 365 13.5k
George L. Daikos 4399 2030 2391 134 6.6k
Andrea M. Hujer 6260 1662 2239 159 8.3k
Y. Glupczynski 4339 1961 1283 253 10.2k
Anton Y. Peleg 6670 2980 1954 220 13.4k
Petros I. Rafailidis 3054 3185 1802 116 7.4k
Mario Tumbarello 3764 3471 1871 150 8.2k
Daryl J. Hoban 5623 4609 3853 214 10.9k
Robert K. Flamm 5960 3580 4081 336 11.3k
Luis Martínez‐Martínez 8510 2545 2759 326 11.6k

All Works

Loading papers...

Rankless by CCL
2026